BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Savient Pharmaceuticals, Inc. (SVNT) Drug Sales Drop


3/20/2013 8:00:30 AM

Shares of Savient Pharmaceuticals Inc. sank Tuesday after the company reported slower sales growth for its gout drug Krystexxa. Savient said sales of Krystexxa totaled $4.7 million during the fourth quarter. That an improvement from last year and earlier quarters, but despite an increase in the price of the drug, revenue growth was slower than in the previous quarters. The company reported $3 million in sales of Krystexxa during the fourth quarter of 2011. In 2012 sales rose to $3.1 million in the first quarter, $4 million in the second quarter, and $4.5 million in the third quarter. That means sales improved 30 percent from the first quarter to the second and 13 percent from the second quarter to the third. Krystexxa has been on the market since late 2010, but sales have been disappointing. In July, Savient said it would eliminate 60 jobs, or about 35 percent of its workforce, to reduce its costs. The company increased the price of Krystexxa 29 percent in 2012, and raised it another 30 percent in January, to $3,850 per vial.

Read at BusinessWeek

   
Gout

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES